Status:
WITHDRAWN
Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal Disease
Lead Sponsor:
Tan Tock Seng Hospital
Conditions:
Cardiovascular Diseases
End Stage Renal Disease
Eligibility:
All Genders
21+ years
Phase:
PHASE2
PHASE3
Brief Summary
This study aims to study SGLT2 inhibitors in patients who are undergoing haemodialysis for end stage renal disease and established ASCVD, to examine the safety and clinical outcomes, consisting of a c...
Detailed Description
Cardiovascular disease accounts for more than 50% of end-stage renal disease (ESRD) deaths. The reported cardiovascular death rates in patients receiving dialysis are substantially higher than in the ...
Eligibility Criteria
Inclusion
- Provision of informed consent prior to any study specific procedures.
- Female or male aged ≥ 21 years.
- Undergoing haemodialysis for end stage renal disease regardless of cause and previous cardiac events.
Exclusion
- Diagnosis of Type 1 diabetes mellitus.
- Pregnant or planning pregnancy or breast-feeding patients.
- Any clinical condition that would jeopardize patient safety while participating in this clinical trial.
- Intake of an investigational drug or participating in another clinical trial involving an investigational drug.
- Life limiting disease other than ESRD with life expectancy estimated to be less than 12 month.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2026
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04764097
Start Date
June 1 2021
End Date
June 1 2026
Last Update
October 21 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.